Double-blinded, placebo-controlled, cross-over pilot study on the efficacy of zileuton for canine atopic dermatitis

Veterinary Dermatology

Volumn 12, Issue 4, 2001, Pages 189-195

  Crow, Dennis W ^a,b   Marsella, Rosanna ^a   Nicklin, Constance F ^a  

^a University of Florida   (United States)

^b Animal Dermatology Referral Clinic   (United States)

Author keywords

5 lipoxygenase inhibitor; Canine atopic dermatitis; Leukotrienes; Skin

Indexed keywords

CANIS FAMILIARIS;

DRUG DERIVATIVE; HYDROXYUREA; LEUKOTRIENE RECEPTOR BLOCKING AGENT; ZILEUTON;

ANIMAL; ANIMAL DISEASE; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOG; DOG DISEASE; DOUBLE BLIND PROCEDURE; FEMALE; MALE; ORAL DRUG ADMINISTRATION; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; CROSS-OVER STUDIES; DERMATITIS, ATOPIC; DOG DISEASES; DOGS; DOUBLE-BLIND METHOD; FEMALE; HYDROXYUREA; LEUKOTRIENE ANTAGONISTS; MALE; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 0035434065     PISSN: 09594493     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0959-4493.2001.00254.x     Document Type: Article

References (41)

1. Scott, D.W., Paradis, M. A survey of canine and feline skin disorders seen in a university practice: small animal clinic, University of Montreal, Saint-Hyacinthe, Quebec (1987-1988). Canadian Veterinary Journal 1990; 31: 830-5.
2. Griffin, C.E. Atopic disease. Seminars in Veterinary Medicine and Surgery 1991; 6: 290-5.
3. Willemse, A., Noordzij, A., Van den Brom, W.E. et al. Allergen specific IgGd antibodies in dogs with atopic dermatitis as determined by the enzyme linked immunosorbent assay (ELISA). Clinical and Experimental Immunology 1985; 59: 359-63.
4. Jansen, H.M., Kapsenberg, M.L. T-Cell regulation in allergic reactions. Netherland Journal of Medicine 1994; 45: 319-28.
5. Cooper, K.D. Atopic dermatitis: recent trends in pathogenesis and therapy. Journal of Investigative Dermatology 1994; 102: 128-37.
6. deShazo, R.D. Future trends in allergy and immunology. Journal of the American Medical Association 1997; 278: 2024-5.
7. Shichijo, M., Ebisawa, M., Miura, K. et al. Relationship between histamine release and leukotriene production from human basophils derived from atopic dermatitis donors. International Archives of Allergy and Immunology 1995; 107: 587-91.
8. Fogh, K., Herlin, T., Kragballe, K. Eicosanoids in skin of patients with atopic dermatitis: prostaglandin E2 and leukotriene B4 are present in biologically active concentrations. Journal of Allergy and Clinical Immunology 1989; 83: 450-5.
9. Kietzmann, M. Eicosanoid levels in canine inflammatory skin disease. In: Von Tsharner, C., Halliwell, R.E.W., eds. Advances in Veterinary Dermatology, Vol. 1. London: Bailliere Tindall, 1990: 211-20.
10. Lewis, R.A., Austen, K.F., Soberman, R.J. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human disease. New England Journal of Medicine 1990; 323: 645-55.
11. 2 in normal human epidermis and in lesion-free epidermis of patients with psoriasis or eczema. British Journal of Dermatology 1985; 112: 135-47.
12. 4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis. Journal of Allergy and Clinical Immunology 1999; 103: 663-70.
13. Scott, D.W. Observations on canine atopy. Journal of the American Animal Hospital Association 1981; 17: 91-100.
14. Fish, J.E., Kemp, J.P., Lockey, R.F. et al. Zafirlukast for symptomatic mild to moderate asthma: a 13-week multicenter study. Clinical Therapeutics 1997; 19: 675-90.
15. Spector, S.L., Smith, L.J., Glass, M. Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. American Journal of Respiratory and Critical Care Medicine; 1994; 150: 618-23.
16. Israel, E., Rubin, P., Kemp, J.P. et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Annals of Internal Medicine 1993; 119: 1059-66.
17. Carucci, J.A., Washenik, K., Weinstein, A. et al. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Archives of Dermatology 1998; 134: 785-6.
18. Holgate, S.T., Bradding, P., Sampson, A.P. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. Journal of Allergy and Clinical Immunology 1996; 98: 1-13.
19. Carter, G.W., Young, P.R., Albert, D.H. et al. 5-Lipoxygenase inhibitory activity of zileuton. Journal of Pharmacology and Experimental Therapeutics 1991; 256: 929-37.
20. Larsen, J.S., Jackson, S.K. Antileukotriene therapy for asthma. American Journal of Health - Systemic Pharmaceuticals 1996; 53: 2821-30.
21. Tagari, P., Brideau, C., Chan, C. et al. Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors. Agents Actions 1993; 40: 62-71.
22. Bell, R.L., Young, P.R., Albert, D. et al. The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. International Journal of Immunopharmacology 1992; 14: 505-10.
23. Willemse, T. Atopic skin disease: a review and reconsideration of diagnostic criteria. Journal of Small Animal Practice 1986; 27: 771-8.
24. Rosser, E.J. Diagnosis of food allergy in dogs. Journal of the American Veterinary Medical Association 1993; 203: 259-62.
25. Willis, J., Harvey, R. Diagnosis and management of food allergy and intolerance in dogs and cats. Australian Veterinary Journal 1994; 71: 322-6.
26. Scheidt, V.J., Medleau, L., Seward, R.L. et al. An evaluation of ivermectin in the treatment of sarcoptic mange in dogs. American Journal of Veterinary Research 1984; 45: 1201-2.
27. de Jaham, C., Henry, C.J. Treatment of canine sarcoptic mange using milbemycin oxime. Canadian Veterinary Journal 1995; 36: 42-3.
28. Morikawa, K., Watabe, H., Araake, M. et al. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrobial Agents Chemotherapy 1996; 40: 1366-70.
29. Kennis, R.A., Rosser, E.J., Oliver, N.B. et al. Quantity and distribution of Malassezia organisms on the skin of clinically normal dogs. Journal of the American Veterinary Medical Association 1996; 208: 1048-51.
30. Barbet, J.L., Haliwell, R.E. Duration of inhibition of immediate skin test reactivity by hydroxyzine hydrocholride in dogs. Journal of the American Veterinary Medical Association 1989; 194: 1565-9.
31. White, P.D. Essential fatty acids: use in management of canine atopy. The Compendium on Continuing Education for the Practising Veterinarian 1993; 15: 451-6.
32. DeBoer, D.J., Moriello, K.A., Pollet, R.M. Efficacy of AHR-13268, an antiallergic compound, in the management of pruritus caused by atopic disease in dogs. American Journal of Veterinary Research 1992; 53: 532-6.
33. Wilcox, C.J., Thatcher, W.W., Martin, F.G. Statistical analysis of repeated measurements in physiology experiments. In: Proceedings of the Final Research Coordination Meeting of FAO/IAEA ARCAL III. Vienna: International Atomic Energy Agency, 1990: 144-55.
34. Conover, W.J., Inman, R.L. Rank transformations as a bridge between parametric and nonparametric statistics. American Statistician 1981; 35: 124-9.
35. Denman, S.T. A review of pruritus. Journal of American Academy of Dermatology 1986; 14: 375-92.
36. Hagermark, O. Peripheral and central mediators of itch. Skin Pharmacology 1992; 5: 1-8.
37. Scott, D.W., Miller, W.H. Medical management of allergic pruritus in the cat, with emphasis on feline atopy. Journal of the South African Veterinary Association 1993; 64: 103-8.
38. 4) in human skin. Journal of Investigative Dermatology 1983; 80: 115-19.
39. 4. Journal of Investigative Dermatology 1984; 82: 202-4.
40. 2. Acta Dermato-Venereologica (Stockholm) 1977; 57: 37-43.
41. 1. Archives of Dermatology 1981; 117: 208-9.